Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.

Br J Cancer · 2020 · PMC7434894 · PMID 32457362

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

29 , 36 However, our results show that the combination of regorafenib with 13- cis -retinoic acid is additive, but did not reach statistical significance for synergy, possibly due to the effects of regorafenib on other kinase targets, such as the PI3K/mTOR/Akt and Fos/Jun pathways.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.